Wintermute Biomedical are excited our ZosterEase Phase Ib clinical trial’s patient recruitment is now fulfilled.
Preliminary safety results expected shortly. Read more here.
Preliminary safety results expected shortly. Read more here.
Wintermute's CEO excited about potential key to addressing Candida auris' devastating spread in the vulnerable population.
"Candida auris (C. auris) is in the news again", says Dr Tom Rau (CEO), "as an emerging fungal pathogen that colonizes human skin and rapidly kills individuals with weakened immune systems. C. auris is a particularly troubling fungal pathogen as most disinfectants/sanitizers do not kill it. Decolonizing C. auris from the skin has not been possible due to a lack of safe and effective compounds. Thus, C. auris spreads easily from person to person, particularly amongst our vulnerable, often leading to fatal infections.
The National Institutes of Health (NIH) have successfully tested several of Wintermute's fatty acid ammonium carboxylate salts against C. auris and found that they completely killed the fungus. This effect, combined with an extended duration of effect on surfaces, suggests there may be significant utility in using Wintermute's patented ammonium carboxylate salts of fatty acids to rapidly decolonize human skin, reduce the spread of C. auris, and save lives. Emerging threats require new solutions."
To read more about C. auris' impact on healthcare, click here.